[go: up one dir, main page]

BR9908690A - Composição farmacêutica contendo estatina e aspirina - Google Patents

Composição farmacêutica contendo estatina e aspirina

Info

Publication number
BR9908690A
BR9908690A BR9908690-5A BR9908690A BR9908690A BR 9908690 A BR9908690 A BR 9908690A BR 9908690 A BR9908690 A BR 9908690A BR 9908690 A BR9908690 A BR 9908690A
Authority
BR
Brazil
Prior art keywords
aspirin
pharmaceutical composition
statin
composition containing
reduce
Prior art date
Application number
BR9908690-5A
Other languages
English (en)
Inventor
Ismat Ullah
Nemichand B Jain
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21912994&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9908690(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR9908690A publication Critical patent/BR9908690A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA CONTENDO ESTATINA E ASPIRINA" é providenciada uma composição farmacêutica útil para baixar o colesterol e reduzir o risco de um enfarte do miocárdio, que inclui uma estatina, como pravastatina, lovastatina, simvastatina, atorvastatina, cerivastatina ou fluvastatina, em combinação com aspirina, de modo a reduzir a interação da aspirina com estatina e diminuir os efeitos colaterais da aspirina. Providencia-se também um método para reduzir o colesterol e reduzir o risco de um enfarte do miocárdio empregando tal composição.
BR9908690-5A 1998-03-18 1999-03-09 Composição farmacêutica contendo estatina e aspirina BR9908690A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/040,794 US6235311B1 (en) 1998-03-18 1998-03-18 Pharmaceutical composition containing a combination of a statin and aspirin and method
PCT/US1999/005111 WO1999047123A1 (en) 1998-03-18 1999-03-09 Pharmaceutical composition containing a statin and aspirin

Publications (1)

Publication Number Publication Date
BR9908690A true BR9908690A (pt) 2000-12-05

Family

ID=21912994

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9908690-5A BR9908690A (pt) 1998-03-18 1999-03-09 Composição farmacêutica contendo estatina e aspirina

Country Status (12)

Country Link
US (2) US6235311B1 (pt)
EP (1) EP1071403B1 (pt)
JP (1) JP4541543B2 (pt)
AR (1) AR018777A1 (pt)
AT (1) ATE300284T1 (pt)
AU (1) AU760520B2 (pt)
BR (1) BR9908690A (pt)
CA (1) CA2324283C (pt)
DE (1) DE69926351T2 (pt)
ES (1) ES2245092T3 (pt)
PE (1) PE20000349A1 (pt)
WO (1) WO1999047123A1 (pt)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268392B1 (en) * 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US6235706B1 (en) 1996-09-18 2001-05-22 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
US7608640B2 (en) * 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
US6569461B1 (en) 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
CN1092986C (zh) * 1999-08-16 2002-10-23 上海本草生物医学工程研究所 一种用于降血脂的辅酶a口服制剂及制备方法和应用
US6696086B1 (en) * 1999-09-10 2004-02-24 Lek Pharmaceuticals D.D. Solid pharmaceutical formulation containing lovastatin and simvastatin, respectively, and its preparation
US20020028240A1 (en) * 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
NZ518216A (en) 2000-08-09 2004-11-26 Panacea Biotec Ltd Pharmaceutical compositions of anti-tubercular drugs and process for their preparation
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
RS50406B (sr) 2001-01-26 2009-12-31 Schering Corporation, Upotreba supstituisanih jedinjenja azetidinona za lečenje sitosterolemije
SI1413331T1 (sl) 2001-01-26 2008-02-29 Schering Corp Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
KR20030096294A (ko) * 2001-03-27 2003-12-24 랜박시 래보러터리스 리미티드 프라바스타틴의 안정한 약학적 조성물
US20080199522A1 (en) * 2001-04-12 2008-08-21 Astellas Pharma, Inc. Timed-release compression-coated solid composition for oral administration
EP1404303A4 (en) * 2001-06-21 2006-03-15 Andrx Pharmaceuticals Inc STABLE PHARMACEUTICAL COMPOSITIONS BASED ON PRAVASTATIN
US20040180087A1 (en) * 2001-06-21 2004-09-16 Boyong Li Stable controlled release pharmaceutical compositions containing pravastatin
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6576256B2 (en) 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
AR036354A1 (es) * 2001-08-31 2004-09-01 Takeda Chemical Industries Ltd Preparacion solida
MXPA04002573A (es) 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US20030153617A1 (en) * 2001-12-18 2003-08-14 Dalen Frans Van Simvastatin dosage forms
SI1467712T2 (sl) * 2002-01-16 2011-11-30 Boehringer Ingelheim Pharma Postopek za pripravo dvoplastne farmacevtske tablete ki obsega telmisartan in hidroklorotiazid
BE1015608A6 (fr) * 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
MY131170A (en) * 2002-03-28 2007-07-31 Nissan Chemical Ind Ltd Therapeutic agent for glomerular disease
EP1501546B1 (de) * 2002-05-03 2012-10-10 Hexal AG Stabile pharmazeutische formulierung für eine kombination aus einem statin mit einem ace-hemmer
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US20070172453A1 (en) * 2002-08-30 2007-07-26 Vincent Geenen Tolerogenic approach for type 1 diabetes
US8980870B2 (en) 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
EP1562582A1 (en) 2002-11-06 2005-08-17 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
JP4494712B2 (ja) * 2002-11-12 2010-06-30 大日本住友製薬株式会社 マルチプルユニット型徐放性製剤
US20040115265A1 (en) * 2002-12-11 2004-06-17 Loutfy Benkerrour Multilayered tablet containing pravastatin and aspirin and method
AU2003297916A1 (en) * 2002-12-12 2004-07-09 Activbiotics, Inc. Method and reagents for treating or preventing atherosclerosis and diseases associated therewith
KR20050088190A (ko) * 2002-12-20 2005-09-02 화이자 프로덕츠 인코포레이티드 콜레스테릴 에스터 전달 단백질 억제제 및 ｈｍｇ-ｃｏａ환원 효소 억제제를 포함하는 투약 형태
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
ES2311806T3 (es) 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
US7192944B2 (en) 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
DK1615632T3 (da) * 2003-04-17 2007-04-10 Jallal Messadek Flydende orale formularer for kontrolleret udskillelse af betain
US20040241234A1 (en) * 2003-06-02 2004-12-02 Alpharma, Inc. Controlled release press-coated formulations of water-soluble active agents
BR8302502U (pt) * 2003-06-10 2005-04-19 Medley S A Ind Farmaceutica Embalagem, ou kit de medicamentos, ou apresentação facilitadora da administração de medicamentos por parte de indivìduos em prevenção e/ou tratamento da doença aterosclerótica
US20060178424A1 (en) * 2003-06-18 2006-08-10 Stanley Nattel Preventing atrial fibrillation (af) with the use of stain drugs
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TWI398273B (zh) * 2003-07-18 2013-06-11 Santarus Inc 用於抑制酸分泌之醫藥調配物及其製備及使用之方法
AR045061A1 (es) * 2003-07-18 2005-10-12 Santarus Inc Formulacion farmaceutica y metodo para tratar trastornos gastrointestinales causados por acido
US7041286B2 (en) * 2003-07-23 2006-05-09 Nerenberg Arnold P Composition for mitigating a pernicious thrombotic event
EP1648422A4 (en) 2003-07-28 2007-09-19 Reddys Lab Inc Dr TREATMENT AND PREVENTION OF CARDIOVASCULAR ACCIDENTS
US20060128657A1 (en) * 2003-08-04 2006-06-15 Jallal Messadek Selected betaines and their uses
JP4829115B2 (ja) * 2003-10-10 2011-12-07 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 選択的ｉ１イミダゾリンレセプターアゴニストおよびアンギオテンシンｉｉレセプターブロッカーを含有する医薬組成物
US20050113452A1 (en) * 2003-10-20 2005-05-26 Moshe Flashner-Barak Composition and dosage form for sustained effect of levodopa
US7670624B2 (en) * 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
CA2554271A1 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
US8535716B2 (en) * 2004-04-01 2013-09-17 Tsrl, Inc. Methods and composition of extended delivery of water insoluble drugs
CA2561700A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2571447A1 (en) * 2004-06-28 2006-01-05 Howard J Smith & Associates Pty Ltd Composition and method for treatment and prevention of atherosclerosis
BE1016128A6 (fr) * 2004-07-22 2006-03-07 Messadek Jallal Combinaisons therapeutiques
US20060020031A1 (en) * 2004-07-26 2006-01-26 Roger Berlin Compositions containing policosanol and omega-3 fatty acids and their pharmaceutical uses
US20060025486A1 (en) * 2004-07-27 2006-02-02 Roger Berlin Compositions containing policosanol and B vitamins and their pharmaceutical uses
US20060034913A1 (en) * 2004-08-13 2006-02-16 James Gaede Multiplex drug delivery device
US20060039890A1 (en) * 2004-08-20 2006-02-23 Renshaw Perry F Treatment of psychological and cognitive disorders using a cholesterol -lowering agent in combination with an antidepressant
DE102004042139B4 (de) * 2004-08-31 2009-06-10 Aristocon Verwaltungs- Gmbh Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit
US20060069042A1 (en) * 2004-09-24 2006-03-30 Hu Oliver Y Cytochrome P450 2C9 inhibitors
US8057820B2 (en) * 2004-10-08 2011-11-15 Mcneil-Ppc, Inc. Enteric coated aspirin granules comingled with binder
US8758814B2 (en) 2004-10-08 2014-06-24 Mcneil-Ppc, Inc. Chewable enteric coated aspirin tablets
ES2255426B1 (es) 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
WO2006050581A2 (en) * 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
KR100646576B1 (ko) 2005-02-15 2006-11-23 한국유나이티드제약 주식회사 고지혈증 환자의 동맥경화증 예방을 위한 에이치엠지이-씨오에이 환원효소 저해제 및 장용코팅된 아스피린을 함유하는 복합 펠렛
EP2242489A1 (en) 2005-02-15 2010-10-27 Jallal Messadek Combination therapeutic compositions and method of use
KR100648825B1 (ko) 2005-02-22 2006-11-24 한국유나이티드제약 주식회사 당뇨병 환자의 동맥경화증 예방을 위한 혈당강하제, 에이치엠지이-씨오에이 환원효소 저해제 및 장용코팅된 아스피린을 함유하는 복합 펠렛
EP1853544A4 (en) 2005-02-24 2010-06-16 Diffusion Pharmaceuticals Llc TRANSCAROTENOIDS AND THEIR SYNTHESIS, THEIR PREPARATION AND USES THEREOF
WO2006099244A1 (en) * 2005-03-11 2006-09-21 Hong Kong Nitric Oxide Limited Combination therapy for endothelial dysfunction, angina and diabetes
CN101180073A (zh) * 2005-04-27 2008-05-14 贾拉尔·梅萨德克 胰岛素组合
EP1741427A1 (en) * 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
WO2007011886A2 (en) * 2005-07-18 2007-01-25 Reliant Pharmaceuticals, Inc. Treatment with azetidinone-based cholesterol absorption inhibitors and omega-3 fatty acids and a combination product thereof
AR057520A1 (es) * 2005-09-15 2007-12-05 Otsuka Pharma Co Ltd Farmaco combinado
WO2007059372A2 (en) * 2005-11-09 2007-05-24 St. Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
US20070116756A1 (en) * 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
US8784886B2 (en) * 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
JP5628480B2 (ja) * 2006-03-09 2014-11-19 グラクソスミスクライン エルエルシー 医薬成分を含有するコーティングカプセル
US20070254897A1 (en) * 2006-04-28 2007-11-01 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of cardiovascular disease
BRPI0602179A (pt) * 2006-06-08 2008-01-22 Biolab Sanus Farmaceutica Ltda composição farmacêutica compreendendo ciclobenzaprina e aceclofenaco em combinação
US20070287727A1 (en) * 2006-06-08 2007-12-13 Jacob Hiller Anti-Nicotine Treatment
EP2051583A4 (en) * 2006-08-16 2011-09-14 Aspreva Pharmaceuticals Ltd COMPOSITIONS AND METHODS FOR TREATING VASCULAR, AUTOIMMUNE AND INFLAMMATORY DISEASES
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
CA2618240C (en) 2006-11-17 2015-01-20 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
US20090042849A1 (en) * 2006-12-06 2009-02-12 Yochai Birnbaum Phosphorylation of 5-lipoxygenase at ser523 and uses thereof
KR100870396B1 (ko) * 2006-12-07 2008-11-25 보령제약 주식회사 심혈관계 질환 치료용 경구투여제제
WO2008095263A1 (en) * 2007-02-09 2008-08-14 Alphapharm Pty Ltd A dosage form containing two or more active pharmaceutical ingredients in different physical forms
KR100955669B1 (ko) * 2007-08-13 2010-05-06 한올바이오파마주식회사 ＨＭＧ­ＣｏＡ 환원효소 저해제와 아스피린을 포함하는 복합제제 및 그의 제조방법
SI2200588T1 (sl) 2007-09-25 2019-08-30 Solubest Ltd. Sestavki, ki obsegajo lipofilne aktivne spojine, in postopek za njihovo pripravo
TWI481407B (zh) * 2007-10-17 2015-04-21 Todd F Ovokaitys 改質化合物之固體狀態的方法及以此製得之共－非晶形組合物
WO2009052246A1 (en) * 2007-10-17 2009-04-23 Ovokaitys, Todd, F. Process for the modification of the solid state of a compound and co-amorphous compositions produced with same
WO2009065193A1 (en) * 2007-11-21 2009-05-28 Jallal Messadek Treatment of aspirin resistance with betaine and/or betaine enriched molasses
US20090226515A1 (en) * 2008-03-04 2009-09-10 Pharma Pass Ii Llc Statin compositions
MX2010010479A (es) * 2008-03-28 2011-02-22 Ferrer Int Capsula para la prevencion de enfermedades cardiovasculares.
TWI445716B (zh) * 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
WO2010084500A1 (en) * 2009-01-22 2010-07-29 Sanofi-Synthelabo (India) Ltd. New combination of active ingredients containing a non steroidal anti inflammatory drug and a colchicoside derivative
CN101491508B (zh) * 2009-01-23 2011-04-20 上海微丸医药开发有限公司 一种阿司匹林肠溶微丸胶囊的制备方法
US20110196383A1 (en) * 2009-05-05 2011-08-11 Atherolysis Medical, Inc Atherosclerotic Plaque Dissolution Composition
CN101897710A (zh) * 2009-05-27 2010-12-01 北京奥萨医药研究中心有限公司 含有HMG-CoA还原酶抑制剂、阿司匹林、叶酸的药物组合物及其用途
CN108464976A (zh) 2009-06-22 2018-08-31 扩散药品有限公司 扩散促进化合物及其单独或与溶栓药一起的应用
WO2010151095A1 (en) 2009-06-25 2010-12-29 Tetra, Sia Novel acetylsalicylic acid salts
KR101193493B1 (ko) 2010-02-02 2012-10-22 한미사이언스 주식회사 소수성 첨가제가 함유된 분리막으로 코팅된 아스피린 및 ＨＭＧ?ＣｏＡ 환원효소 억제제를 포함하는 복합제제
CA2794255C (en) 2010-03-25 2020-01-14 Minnie M. Sarwal Protein and gene biomarkers for rejection of organ transplants
US8974822B2 (en) 2010-06-02 2015-03-10 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
TR201005325A2 (tr) * 2010-06-30 2012-01-23 Bi̇lgi̇ç Mahmut Atorvastatin ve aspirin içeren farmasötik formülasyonlar
KR20120068277A (ko) * 2010-12-17 2012-06-27 한미사이언스 주식회사 ＨＭＧ－ＣｏＡ 환원효소 억제제 및 아스피린을 포함하는 약제학적 복합제제
US20130345182A1 (en) * 2010-12-21 2013-12-26 Silanes Laboratories Stable composition comprising cholesterol-lowering agents, antihypertensive agents and antiplatlet agents
KR101298788B1 (ko) * 2011-03-15 2013-08-22 보령제약 주식회사 안정성이 개선된 복합제제
AR086675A1 (es) * 2011-06-14 2014-01-15 Merck Sharp & Dohme Composiciones farmaceuticas de combinaciones de inhibidores de la dipeptidil peptidasa-4 con simvastatina
TWI630002B (zh) 2011-11-30 2018-07-21 武田藥品工業股份有限公司 乾塗覆錠
WO2013112933A1 (en) * 2012-01-27 2013-08-01 The Board Of Trustees Of The Leland Stanford Junior University Identification of new therapeutic uses for known therapeutic agents
WO2013133620A1 (en) * 2012-03-09 2013-09-12 Yuhan Corporation Pharmaceutical composition comprising clopidogrel and aspirin and process for preparing the same
US20150190532A1 (en) * 2012-04-04 2015-07-09 The Trustees Of Columbia University In The City Of New York Smooth muscle specific inhibition for anti-restenotic therapy
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US20140274990A1 (en) * 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions
EP2810644A1 (en) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
LV14963B (lv) 2013-06-28 2015-10-20 Tetra, Sia Endoteliālās disfunkcijas korektors
US20150072005A1 (en) * 2013-09-10 2015-03-12 Vitalis Llc Aspirin formulation for increased efficacy
US10202598B2 (en) 2014-05-30 2019-02-12 Todd Frank Ovokaitys Methods and systems for generation, use, and delivery of activated stem cells
WO2015185240A1 (en) 2014-06-04 2015-12-10 Sigma-Tau Industrire Farmaceutiche Riunite S.P.A. Compositions containing simvastatin in omega-3 polyunsaturated fatty acids
US10384985B2 (en) 2014-06-06 2019-08-20 B.K. Consultants, Inc. Methods and compositions for increasing the yield of, and beneficial chemical composition of, certain plants
WO2015187974A1 (en) 2014-06-06 2015-12-10 Ovokaitys Todd Frank Methods and compositions for increasing the bioactivity of nutrients
BE1023011B1 (nl) * 2015-08-05 2016-11-04 Nordic Specialty Pharma Bvba Acetylsalicylzuur tablet met onmiddellijke afgifte
FR3040303B1 (fr) * 2015-08-27 2019-04-05 Les Laboratoires Servier Suivi Par Sabine Goudeau-Wenger Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca
KR102489034B1 (ko) 2016-03-24 2023-01-13 디퓨젼 파마슈티컬즈 엘엘씨 암을 치료하기 위한, 화학 요법 및 방사선 요법과의 양극성 트랜스 카로티노이드의 용도
FR3060390B1 (fr) * 2016-12-19 2020-09-25 Bh Pharma Formulation comprenant de la pravastatine et de l'acide acetylsalycilique
MX2019009213A (es) * 2017-01-23 2019-09-27 Dong Wha Pharm Co Ltd Formulación compleja que comprende inhibidor de la hmg-coa reductasa y clopidogrel.
US11185530B2 (en) * 2017-03-09 2021-11-30 Ajou University Industry-Academic Cooperation Foundation Composition for preventing or treating hearing loss, containing atorvastatin as active ingredient
EP4259162A4 (en) 2020-12-08 2024-11-06 Todd F. Ovokaitys METHODS AND SYSTEMS FOR ENHANCED STEM CELL PRODUCTION

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642233A (en) * 1982-03-22 1987-02-10 Alza Corporation Gastrointestinal drug delivery system comprising a hydrogel reservoir containing a plurality of tiny pills
DK8603837A (pt) * 1985-08-13 1987-02-14
US5238686A (en) * 1986-03-27 1993-08-24 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
CA2016467A1 (en) * 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
US5415870A (en) * 1991-07-01 1995-05-16 Gerhard Gergely Effervescent systems using reaction doping agents
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
HU217629B (hu) * 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
JP3152978B2 (ja) * 1991-12-17 2001-04-03 塩野義製薬株式会社 二層錠およびその製造方法
AU3473193A (en) 1992-01-17 1993-08-03 Procter & Gamble Company, The Treatment for atherosclerosis
US5593696A (en) * 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
JPH08325145A (ja) * 1995-05-26 1996-12-10 Sumitomo Pharmaceut Co Ltd 安定なイソプロピルアンチピリン含有製剤
WO1997038694A1 (en) * 1996-04-17 1997-10-23 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
JP2001500875A (ja) 1996-09-18 2001-01-23 メルク エンド カンパニー インコーポレーテッド 心臓血管系疾患関連の危険性を減らす併用治療法

Also Published As

Publication number Publication date
JP4541543B2 (ja) 2010-09-08
US6235311B1 (en) 2001-05-22
WO1999047123A1 (en) 1999-09-23
CA2324283C (en) 2009-11-03
ATE300284T1 (de) 2005-08-15
CA2324283A1 (en) 1999-09-23
AR018777A1 (es) 2001-12-12
JP2002506809A (ja) 2002-03-05
EP1071403B1 (en) 2005-07-27
DE69926351D1 (de) 2005-09-01
AU2901599A (en) 1999-10-11
EP1071403A4 (en) 2002-09-18
US20020034546A1 (en) 2002-03-21
EP1071403A1 (en) 2001-01-31
AU760520B2 (en) 2003-05-15
ES2245092T3 (es) 2005-12-16
DE69926351T2 (de) 2006-04-20
PE20000349A1 (es) 2000-06-29

Similar Documents

Publication Publication Date Title
BR9908690A (pt) Composição farmacêutica contendo estatina e aspirina
PT738512E (pt) Utilizacao de um inibidor da hmg-coa-reductase para evitar um segundo ataque cardiaco
IE970731A1 (en) Product and method for the treatment of hyperlipidemia
PE106999A1 (es) Composicion de amlodipina y una estatina
PT97660A (pt) Processo para a preparacao de composicoes farmaceuticas contendo um agente hipocolesterolizante e um inibidor da enzima de conversao da angiotensina
BG105559A (en) STABLE PHARMACEUTICAL FORMULATION COMPRISING A HMG-CoA REDUCTASE INHIBITOR
MX2009003920A (es) Estatina y acidos grasos omega 3 para reducir los niveles de apo b.
FI970825A7 (fi) Farmaseuttiset koostumukset, jotka aktiivisen yhdisteen biologisen hyö tyosuuden lisäämiseksi sisältävät sappisuolaa ja puskuria
DE69530389D1 (de) Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen
EP0433842A3 (en) 1,2,3-triazole derivatives active as inhibitors of the enzyme hmg-coa reductase and pharmaceutical compositions containing them
EP0680754A3 (en) Preparation for percutaneous absorption containing buprenorphine.
PE20001325A1 (es) Combinacion de cerivastatina y fibratos
KR970705990A (ko) 피부 질환 치료용 조성물(Compositions for the Treatment of Skin Disorders)
BR9813542A (pt) Combinações de estatina-éter carboxialquìlico
IS6227A (is) Hýdroxýltenging kompaktíns við pravastatín með Micromonospora
AU6035898A (en) Table of contents caching method for enhancing access to cd-rom's and the like
NO996206L (no) Farnesyltransferase inhibitorer i kombinasjon med HMG COA reduktase inhibitorer for behandling av cancer
ITRM920222A0 (it) Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.
ECSP992883A (es) Composicion farmaceutica que contiene una combinacion de una estatina y aspirina y metodo
ES2192018T3 (es) Composicion farmaceutica que contiene estimuladores de interferon-gamma.
BR9813539A (pt) Combinações de inibidor de lp(a) e estatina anti-hiperlipidêmicas
BG106918A (en) Perocess for the preparation of sodium salts of statins
EP1022017A3 (de) Kosmetische oder pharmazeutische Zubereitungen für die topische Verabreichung mit verbesserter Stabilität
PE20050688A1 (es) Composiciones hipocolesterolemiantes
CA2375378A1 (en) Antilipemic combinations comprising hmg-coa reductase inhibitors and carnitines

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADO DA INT. CL: A61K 9/24; A61K 9/28; A61K 9/16; A61P 3/06; A61P 9/10.

Ipc: A61K 9/16 (2009.01), A61K 9/24 (2009.01), A61K 9/2

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIDO O PEDIDO COM BASE NOS ARTIGOS 8O E 13 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.